Two orphan drugs are among a host of products that the European Medicines Agency’s human medicines committee has OKd for pan-EU approval.

The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally to Day One Biopharmaceuticals' Ojemda for refractory pediatric low-grade glioma.

The JAK inhibitor cream for hand eczema will serve a large market in Europe and help the Danish dermatology specialist expand its strong position in dermatology. 

Second generation combination products may become more appealing as companies navigate the complexities of the Medicare price negotiation program.